Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Discovery Corporation, a molecular diagnostics company, has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics.
Subscribe to our email newsletter
Under the terms of the agreement, Health Discovery Corporation (HDC) will receive payments, royalties and additional undisclosed financial considerations.
Stephen Barnhill, chairman and CEO of HDC, said: “We are pleased to work with Quest Diagnostics on the development of an exciting new noninvasive test for clinically significant prostate cancer. It is an ideal clinical laboratory to use our markers for developing a test as an aid in detecting prostate cancer.”